Phase 3 study for people with Heart Disease

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor University of Sydney
Registry number NCT03998319
Started 14 October 2021 Today 16 October 2026 Estimated completion 31 December 2024

Past estimated completion. The registry still lists this trial as open, and the date it gave for finishing has been and gone. Confirm with the official record before you act on it.

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Bankstown-Lidcombe Hospital Bankstown NSW Not yet recruiting
Royal Prince Alfred Hospital Camperdown NSW Recruiting
Concord Repatriation General Hospital Concord NSW Recruiting
Northern Beaches Hospital Frenchs Forest NSW Not yet recruiting
Liverpool Hospital Liverpool NSW Recruiting
John Hunter Hospital New Lambton Heights NSW Recruiting
Prince of Wales Hospital Randwick NSW Not yet recruiting
Wollongong Hospital Wollongong NSW Withdrawn
Royal Adelaide Hospital Adelaide SA Recruiting
Lyell McEwin Hospital Elizabeth Vale SA Recruiting
Box Hill Hospital Box Hill VIC Recruiting
Jessie McPherson Private Hospital Clayton VIC Recruiting
Victorian Heart Hospital Clayton VIC Recruiting
The Northern Hospital Epping VIC Recruiting
Frankston Hospital Frankston VIC Recruiting
Sunshine Hospital Saint Albans VIC Recruiting
Fiona Stanley Hospital Murdoch WA Not yet recruiting
Royal Perth Hospital Perth WA Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 445

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

1. Adult men and women aged over 18 who present with STEMI within 6 hours of symptom onset. Patients will be eligible if they have symptoms consistent with myocardial ischaemia (chest pain, dyspnoea) for at least 20 minutes accompanied by definite ECGs indicating STEMI as defined by Australian National Heart Foundation (NHF) guidelines

2. Willing and able to comply with all study requirements, including treatment, assessment and clinic visit attendances

3. Able to personally read and understand the Participant Information and Consent Form and provide written, signed and dated informed consent to participate in the study

4. (At time of PCI) Patient has received metallic drug-eluting stent

5. Participant consents to have a 3-7 day (discharge) and 6 month follow up cardiac MRI

Exclusion Criteria:

At the time of screening and/or prior to randomisation, no known;

1. Previous coronary bypass grafting

2. Other residual lesions with ≥50% diameter stenosis in the culprit vessel

3. Prior myocardial infarction in the target territory

4. Presence of contraindications to thrombolytic therapy (including history of stroke and recent brain surgery active internal bleeding; history of cerebrovascular accident; intracranial or intraspinal surgery, or trauma within 2 months; intracranial neoplasm, arteriovenous malformation, or aneurysm; known bleeding diathesis; and severe uncontrolled hypertension)

5. Presence of contraindications to adenosine infusion for IMR measurement including sinus node disease, moderate to severe bronchoconstrictive disease and second or third-degree atrioventricular (AV) block

6. Diagnosis of metastatic disease

7. Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety

8. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol

9. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must have been surgically sterilised or use a (double if required) barrier method of contraception.

10. Participation in any investigational study in the previous 30 days

Other exclusion criteria:

11. (Cardiac MRI cohort only) Presence of contraindications to contrast enhanced MRI including severe claustrophobia, pregnancy, pacemakers, non-MRI compatible aneurysm clips, defibrillators and estimated glomerular filtration rate of \<30mL/min.

(At time of PCI)

12. Patients who received GpIIb/IIIa treatment prior to IMR measurement

13. Patients who do not undergo primary PCI due to lack of severity of culprit lesion or other reasons.

Dates on the record

Started 14 October 2021
Estimated completion 31 December 2024
Registry last updated 27 September 2024
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 27 September 2024.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.